ArticleCritical care (London, England)2026
Determinants of diagnostic yield and scan quality of [
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background[18F]-fluorodeoxyglucose Positron Emission Tomography combined with Computed Tomography ([18F]FDG PET/CT) is widely used to detect focal inflammation. However, its diagnostic performance and utility in the ICU remain unclear. We aimed to identify factors influencing diagnostic yield and scan quality of [18F]FDG PET/CT in critically ill patients suspected of infection or inflammation.
methodsWe retrospectively evaluated [18F]FDG PET/CT scans performed in adult ICU patients across four Dutch hospitals (2013–2023). The primary endpoint was diagnostic yield: new conclusive diagnoses and/or therapy changes within 72 h. Secondary endpoints were scan quality and adequacy of myocardial suppression. Logistic regression was used to identify determinants of each endpoint.
resultsWe analyzed 169 scans for 162 clinical indications in 151 patients. A conclusive diagnosis was established for 109 indications (67%), including 79 new diagnoses (49%), most frequently involving the musculoskeletal system (n = 39; 24%) and the respiratory tract (n = 31; 19%). [18F]FDG PET/CT prompted a therapy change in 70 indications (43%). Diabetes (aOR 0.35 [95% CI: 0.15–0.80]) and partial-body imaging versus total-body imaging (aOR 0.48 [CI 0.24–0.99]) were associated with fewer new diagnoses. A longer pre-scan ICU stay predicted therapy change (aOR 1.03 [1.01–1.05]). Higher BMI (aOR 1.08 [1.00–1.17]) and lower serum creatinine (log-transformed aOR 0.36 [0.20–0.68]) were associated with improved scan quality. Male sex (aOR 0.45 [0.21–0.96]) and pre-scan unfractionated heparin (aOR 0.43 [0.19–0.98]) were associated with suboptimal myocardial suppression.
conclusions[18F]FDG PET/CT has a high diagnostic yield in critically ill patients. Diagnostic yield, scan quality and myocardial suppression are influenced by patient characteristics and preparation. Optimizing these factors may further enhance its utility in the ICU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.